cur in hepatitis C virus (HCV) infection. Johnson et al first described 8 patients with membranoproliferative glomerulonephritis (MPGN)and HCVinfection (1) . Most of the cases showed nephrotic syndrome, hypocomplementemia, serum IgM rheumatoid factor and cryoglobulinemia. Although the mechanism by which HCVinduces MPGN has not been known, cryoglobulin containing HCV, anti-HCV antibody and IgM rheumatoid factor mayplay an important role as an immunecomplex.
The question is how to treat this disease. Interferon alpha has been approved for treatment of chronic HCVinfection. Interferon alpha has been used by several investigators to remove HCVas an antigen in HCV-associated glomerulonephritis. In a prospective randomized, controlled trial, Misiani et al (2) studied the effect of interferon alpha in 53 patients with HCV-associated cryoglobulinemia. A group of 27 patients received recombinant interferon al fa thrice weekly at a dose of 1.5-3.0 million units for 24 weeks. Serum HCVRNAturned undetectable in 15 of 25 patients (60%) who completed the therapy, but in none of the controls. In contrast to the control group, the 15 patients with undetectable levels of HCVRNA in serum had significant improvement in clinical manifestations with decreased serum creatinine levels and urinary protein excretion. However,after the cessation of interferon therapy, all of those who had responded to the therapy showed recurrence. Johnson et al also reported the efficacy of interferon alpha in HCV-associated glomerulonephritis (3). Fourteen patients received interferon alpha at the dose of 3 million units thrice a week for 6-12 months with a significant reduction in proteinuria but no improvement in renal function. A good clinical response was correlated with disappearance of HCVRNAfrom serum during the treatment. However, relapse of viremia and renal disease was commonafter completing the therapy. Since then many reports including the effect of highdose interferon (4), ribavirin (5), which is a nucleoside analogue with activity against viruses, and a combination with interferon and ribavirin (6) have been published, and the results were inconsistent. The side effects of interferon alpha are dose dependent and are more frequent with increased duration of therapy. Interferon alpha may also induce renal injury (7). Thus, the optimal dose and duration of interferon therapy in HCV-associated glomerulonephritis have not been established. Another therapeutic strategy is to manipulate the immune mechanisms by using corticosteroids, immunosuppresive agents and plasmapheresis. In a randomized controlled study, Dammacco et al (8) compared the treatment outcome among patients treated with either interferon alpha or prednisolone alone, or in combination. While a complete response was achieved in 8 of 15 (53.3%) patients treated with interferon alpha and in 9 of 17 (52.9%) treated with interferon alpha plus prednisolone, it was found in only 3 of 18 (16.7%) patients who received prednisolone only and in 1 of 15 (6.7%) untreated controls. In the 3 patients in the prednisolone group, improvement of clinical manifestations was observed without significant changes in HCVRNAlevels. In contrast, in 5 of 13 (38.5%) HCVRNA-positive non-responsive patients, a significant increment of HCVRNAlevels was demonstrated. Quigg et al reported a case of membranoproliferative glomerulonephritis with cryoglobulinemia and HCVinfection (9) . In that case cyclophosphamide was very effective and within 1 month of initiating therapy, the patient's cryoglobulin became undetectable in serum. After 3 months the patient's renal function became normal, although serum levels of HCVRNAincreased. Komatsudaet al reported the effectiveness and safety of corticosteroids in HCV-associated nephropathy ( 10). They treated 16 patients with various types of glomerulonephritis and HCV infection with interferon alpha or corticosteroids. Five patients were treated with interferon alpha without a remarkable effect on renal impairment, whereas 5 of 1 1 patients treated with steroids showed a decrease in the serum creatinine level and urinary protein excretion. They also described that during the course of steroid therapy, the serum titer of HCVRNAdecreased in 5 of 7 patients and aggravation of liver function was not observed. Plasmapheresis has also been used for the treatment of mixed cryoglobulinemia. Mori et al describe in this issue of the Journal that the combination of cryofiltration and corticosteroids improved the clinical manifestations, proteinuria and renal function in a patient with HCV-associated glomerulonephritis with a transient decrease of serum HCVRNAlevels(ll).
See also p 564.
Immunosuppressivetherapy maybe useful to treat patients whodo not showa favorable result or can not tolerate interferon, although it is not certain that immunosuppressive therapy ameliorates the long-term prognosis of this disease. 
